Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Altea Therapeutics
Rick Bright is requesting an inspector general investigation into his removal as director of the Biomedical Advanced Research and Development, accusing the Trump administration of favoring politics over science when making COVID-19 funding decisions.
The market for insulin delivery devices is positioned to change significantly with several manufacturers gearing their products toward type 2 diabetics, who make up 90% to 95% of the diabetes patient pool in the US. These new, “pump-like” devices could offer the type 2 diabetes population better control in managing glucose levels, a solution the medical community has been seeking for a while.
Despite the slumping economy, the diabetes market continues to be a very active area, with treatment-changing products recently launched or in late-stage development. Although no industry has been able to escape the effects of the US recession, and certain segments of the diabetes market have seen a decline in sales, other areas continue to move forward. Once the economy returns to healthier levels, the overall market is expected to see a renewal of growth. Meanwhile, an expanded emphasis on emerging international markets could help offset some of the sluggish numbers in the US and parts of Europe.
After enjoying almost five years of exclusivity, Lilly/Amylin's first-in-class antidiabetic GLP-1 receptor analogue Byetta (exenatide) has started to feel competition nipping at its heels. Asher Mullard investigates the future for this growing drug class and the next-generation therapeutics that are jockeying for position.
- Controlled Release
- Large Molecule